Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk-461364. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 18/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 1.00 |
| ▸ | NEK2 | P51955 | 3/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | GRK4 | P32298 | 1/20 | 1.00 |
| ▸ | TIE1 | P35590 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | PRKCI | P41743 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-461364 SCHEMBL29360650 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL310080 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL29655945 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL19196385 | 0.95 | PLK1 (0.91) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL25660820 | 0.94 | PLK1 (0.89) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2973906 | 0.94 | PLK1 (0.88) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2973537 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4562944 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4405982 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL13573235 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369214-A1 | Methods of Diagnosing and Treating Small Cell Lung Cancer Using Polo-Like Kinase 1 (PLK1) Inhibitors | EMORY UNIVERSITY | 2018-12-27 | — | — | US | claimed |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | SECURA BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230293534-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | SECURA BIO, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230159515-A1 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | UPPTHERA (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230159515-A1 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | UPPTHERA (KR) | 2023-05-25 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| WO-2009151914-A1 | METHODS FOR TREATING NEOPLASMS WITH A COMBINATION OF A PLK INHIBITOR AND RETINOID | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1937671-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | SMITHKLINE BEECHAM CORPORATION | 2009-01-01 | — | — | US | disclosed |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | SMITHKLINE BEECHAM CORPORATION | 2009-01-01 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3CA, MCL1, PIK3CB | PLK1 49/4885PLK3 359/4885NEK2 204/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PLK1 61/4885PLK3 1256/4885NEK2 576/4885 |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | TUBB3, TUBB6, TUBB | PLK1 424/4885PLK3 1271/4885NEK2 467/4885 |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | PLK1 1726/4885PLK3 2838/4885NEK2 4130/4885 |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3R5, PIK3R4, PIK3CD | PLK1 283/4885PLK3 413/4885NEK2 1383/4885 |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | ABCB1, ABCG2, CYP3A5 | PLK1 344/4885PLK3 934/4885NEK2 2296/4885 |
| US-20230293534-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PI4KB | PLK1 122/4885PLK3 559/4885NEK2 318/4885 |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885NEK2 2703/4885 |
| US-20230159515-A1 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | PLK1, BUB1, BUB1B | PLK1 1/4885PLK3 18/4885NEK2 298/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885PLK3 359/4885NEK2 204/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | PLK1 1643/4885PLK3 2878/4885NEK2 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.